Roche breast cancer pill cuts post-surgery recurrence risk by 30% in major trial
Roche; giredestrant; breast cancer; hormone receptor-positive; ER-positive; HER2-negative; oral SERD; endocrine therapy; adjuvant therapy; recurrence risk; phase III lidERA trial; disease-free survival; San Antonio Breast Cancer Symposium
Immunovant Announces Pricing of $550 Million Common Stock Financing
Immunovant; IMVT; common stock offering; $550 million financing; equity financing; underwritten offering; IMVT-1402; Roivant Sciences; Leerink Partners; biotech capital raise
Updated Efficacy Data of Ivonescimab Plus Chemotherapy as First-Line Treatment for TNBC at ESMO IO 2025
ivonescimab; Yidafan; PD-1/VEGF bispecific antibody; triple-negative breast cancer; TNBC; first-line treatment; ESMO IO 2025; Phase II trial; chemotherapy combination; objective response rate; progression-free survival; disease control rate; PD-L1 CPS subgroups; safety profile; Breakthrough Therapy Designation; HARMONi-BC1; AK112-308
Concr Adds Former AstraZeneca and Cancer Research Institute Executives to Advisory Board
Concr; AstraZeneca; Cancer Research Institute; advisory board; biotech; oncology; executive appointments; life sciences; strategic advisory; cancer drug development
Recent advances in AI for antimicrobial resistance (AMR) prevention and control
antimicrobial resistance; AI in healthcare; machine learning; antibiotic stewardship; AI antibiotic discovery; phage therapy; rapid diagnostics; AMR surveillance; generative AI
Spotlight On: It’s Raining AI Devices as Regulatory Storm Reshapes Digital Health
AI-enabled medical devices; digital health regulation 2025; FDA AI draft guidance; EU AI Act health; generative AI in healthcare; SaMD regulation; clinical oversight of AI; AI accountability in healthcare; digital mental health devices
FDA reviews safety of approved RSV antibodies for infants
FDA; RSV; nirsevimab; Beyfortus; palivizumab; RSV antibodies; infant safety review; Sanofi; AstraZeneca; Merck; respiratory syncytial virus
Apple Tree files for bankruptcy as it seeks fresh funding from Russian billionaire backer
Apple Tree; bankruptcy filing; insolvency; Russian billionaire backer; restructuring; financing deal; debt obligations; investor rescue
Novartis antibody ianalumab helps prolong control of rare blood disorder ITP
Novartis; ianalumab; primary immune thrombocytopenia; ITP; rare blood disorder; antibody; VAYHIT2 trial; time to treatment failure; disease control; ASH 2025; Promacta; eltrombopag
SanegeneBio raises over $110M Series B after Lilly RNAi deal
SanegeneBio; Series B financing; $110 million; Eli Lilly; RNA interference; RNAi therapeutics; metabolic diseases; Lilly collaboration; clinical-stage assets; liver-targeted RNAi; extrahepatic RNAi; biotech fundraising 2025